Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2017—Only a sadist would want to see gastroesophageal adenocarcinoma become as common as breast cancer. GEA wreaks enough destruction already as the fifth (stomach) and eighth (esophageal) most common cancers worldwide.
January 2017—Extended cruises down the rivers of Europe and life without alarm clocks might figure in a vision of retirement for some people, but don’t include toxicology expert Marilyn A. Huestis, PhD, in that contingent, at least for now.
January 2017—U.S. physicians and laboratories are anticipating the early 2017 launch of the HemosIL HIT-Ab(PF4-H) assay, which detects antibodies associated with heparin-induced thrombocytopenia. The new test from Instrumentation Laboratory, Bedford, Mass., is the first fully automated, on-demand assay for HIT.
January 2017—What does it take to produce and edit the first book on AP quality management that the CAP has published in more than a decade? A diverse network of experts, a commitment to comprehensive quality assurance, and, says co-editor Qihui “Jim” Zhai, MD, a bit of bravery.
January 2017—In February 2002, with Americans still reeling from the Sept. 11 attacks, many were preoccupied with rumors suggesting that the Iraqi dictator had acquired weapons of mass destruction and intended to supply them to terrorists.
January 2017—Detecting pathogenic organisms with PCR has become a staple of the clinical microbiology laboratory, so much so that it seems like it has always been there. A more advanced molecular technique—unbiased metagenomic next-generation sequencing—will increasingly become a part of infectious disease diagnosis because it has several advantages over PCR. While it will be demanding to perform at first, it, too, may become a standard method in the clinical microbiology laboratory.
January 2017—A recent landmark study performed under the auspices of the Endocrine Pathology Society has proposed a new diagnostic entity in the thyroid: noninvasive follicular thyroid neoplasm with papillary-like nuclear features, or NIFTP.
January 2017— What’s in a name? As announced in JAMA Oncology in April 2016, tumors previously classified as follicular variant of papillary thyroid carcinoma and found to have no invasion on adequate sampling of the tumor capsule have been given a new name: noninvasive follicular thyroid neoplasm with papillary-like nuclear features, or NIFTP.
January 2017—It’s the end of the year, say, and you are just a few self-assessment modules, or SAMs, short of the required 20 in your area of expertise—anatomic pathology. You have to meet the requirements for the American Board of Pathology’s Maintenance of Certification and time-limited cytopathology and AP/CP certificates for each two-year reporting cycle. What to do?
January 2017—Complaints about laboratory information technology services are nearly universal. Rare is the person who is happy with his or her laboratory information system or with the way information services are delivered.
